Potential of non-coding RNA as biomarkers in heart failure;Potentiel des ARN non codants comme biomarqueurs dans l'insuffisance cardiaque

Medecine/Sciences

Volumn 31, Issue 8-9, 2015, Pages 770-776

  Pinet, Florence ^a   Bauters, Christophe ^a  

^a UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LONG UNTRANSLATED RNA;

BLOOD; HEART FAILURE; HUMAN;

BIOMARKERS; HEART FAILURE; HUMANS; RNA, LONG NONCODING;

EID: 84941200825     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/20153108016     Document Type: Article

References (38)

1. Nichols M, Townsend N, Luengo-Fernandez R, et al. European cardiovascular disease statistics 2012. Brussels: European Heart Network. Sophia Antipolis: European Society of Cardiology, 2012.
2. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93: 1137-1146.
3. Jhund PS, Macintyre K, Simpson CR, et al. Long-Term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 2009; 119: 515-523.
4. Roger VL. Epidemiology of heart failure. Circ Res 2013; 113: 646-659.
5. De Groote P, Millaire A, Foucher-Hossein C, et al. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol 1998; 32: 948-954.
6. De Groote P, Fertin M, Goéminne C, et al. Right ventricular systolic function for risk stratification in patients with stable left ventricular systolic dysfunction: comparison of radionuclide angiography to echoDoppler parameters. Eur Heart J 2012; 33: 2672-2679.
7. Lee DS, Vasan RS. Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol 2005; 20: 201-210.
8. De Groote P, Dagorn J, Soudan B, et al. B-Type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. J Am Coll Cardiol 2004; 43: 1584-1589.
9. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-2250.
10. Kumarswamy R, Thum T. Non-coding RNAs in cardiac remodeling and heart failure. Circ Res 2013; 113: 676-689.
11. Braunwald E. Research advances in heart failure. Circ Res 2013; 113: 633-645.
12. Tong YK, Lo YM. Diagnostic developments involving cell-free (circulating) nucleic acids. Clin Chem Acta 2006; 363: 187-196.
13. Fertin M, Hennache B, Hamon M, et al. Usefulness of serial assessment of B-Type natriuretic peptide, troponin I, and C-reactive protein to predict left ventricular remodeling after acute myocardial infarction (from the REVE-2 study). Am J Cardiol 2010; 106: 1410-1416.
14. Bauters C, Kumarswamy R, Holzmann A, et al. Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction. Int J Cardiol 2013; 168: 1837-1840.
15. Jacobs L, Thijs L, Jin Y, et al. Heart omics in AGEing (HOMAGE): design, research objectives and characteristics of the common database. J Biomed Res 2014; 28: 349-359.
16. Baulande S, Criqui A. Duthieuw. Les microARN circulants, une nouvelle classe de biomarqueurs pour la médecine. Med Sci (Paris) 2014; 30: 289-296.
17. Mathieu EL, Belhocine M, Dao LTM, et al. Rôle des longs ARN non codants dans le développement normal et pathologique. Med Sci (Paris) 2014; 30: 790-796.
18. Kung JTY, Colognori D, Lee JT. Long non coding RNAs: past, present, and future. Genetics 2013; 193: 651-669.
19. Derrien T, Johnson R, Bussotti G, et al. The Gencode v7 catalog of human long non coding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 2012; 22: 1775-1789.
20. Thum T. Noncoding RNAs and myocardial fibrosis. Nat Rev Cardiol 2014; 11: 655-663.
21. Dubois E, Fertin M, Burdese J, et al. Cardiovascular proteomics: translational study to develop novel biomarkers in heart failure and left ventricular remodeling. Proteomics Clin Appl 2011; 5: 57-66.
22. Savoye C, Equine O, Tricot O, et al. Left ventricular remodeling after anterior wall acute myocardial infarction in modern clinical practice (from the REmodelage VEntriculaire [REVE] study group). Am J Cardiol 2006; 98: 1144-1149.
23. Fertin M, Dubois E, Belliard A, et al. Usefulness of circulating biomarkers for the prediction of left ventricular remodeling after myocardial infarction. Am J Cardiol 2012; 110: 277-283.
24. Kumarswamy R, Bauters C, Volkmann I, et al. The circulating long non-coding LIPCAR predicts survival in heart failure patients. Circ Res 2014; 114: 1569-1575.
25. Yang KC, Yamada KA, Patel AY, et al. Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support. Circulation 2014; 129: 1009-1021.
26. Ounzain S, Micheletti R, Beckmann T, et al. Genome-wide profiling of the cardiac transcriptome after myocardial infarction identifies novel heart-specific long non-coding RNAs. Eur Heart J 2015; 36: 353-368.
27. Wang K, Liu F, Zhou LY, et al. The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res 2014; 114: 1377-1388.
28. Vausort M, Wagner DR, Devaux Y. Long non-coding RNAs in patients with acute myocardial infarction. Circ Res 2014; 115: 668-677.
29. Matkovich SJ, Edwards JR, Grossenheider TC, et al. Epigenetic coordination of embryonic heart transcription by dynamically regulated long noncoding RNAs. Proc Natl Acad Sci USA 2014; 111: 12264-12269.
30. Han P, Li W, Lin CH, et al. A long noncoding RNA protects the heart from pathological hypertrophy. Nature 2014; 514: 102-106.
31. Dorn GW. LIPCAR: a mitochondrial lnc in the noncoding RNA chain? Circ Res 2014; 114: 1548-1550.
32. Lemesle G, Maury F, Beseme O, et al. Multi-marker proteomic profiling for the prediction of cardiovascular mortality in patients with chronic heart failure. PLoS One 2015; 10: e0119265.
33. Gustafsson M, Nestor CE, Zhang H, et al. Modules, networks and systems medicine for understanding disease and aiding diagnosis. Genome Med 2014; 6: 82.
34. Bateman S. Médecine personnalisée: un concept flou, des pratiques diversifiées. Med Sci (Paris) 2014; 30: 8-13.
35. Le Pedrazzini T. cœur des ARN non codants: un long chemin à découvrir. Med Sci (Paris) 2015; 31: 261-267.
36. Ladeiro Y, Zucman-Rossi J. Micro-ARN (miARN) et cancer: le cas des tumeurs hépatocellulaires. Med Sci (Paris) 2009; 25: 467-472.
37. Gougelet A, Colnot S. Les microARN dans le cancer du foie à l'orée de nouvelles thérapies ciblées ? Med Sci (Paris) 2013; 29: 861-867.
38. Billaud M, Guchet X. L'invention de la médecine personnalisée: entre mutations technologiques et utopie. Med Sci (Paris) 2015; 31: 797-803.